PDF herunterladen
Ernährung & Medizin 2022; 37(02): 93-99
DOI: 10.1055/a-1756-0254
Wissen

Wechselwirkungen von Vitamin E mit Arzneistoffen

Jan Frank
,
Maren C. Podszun
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Über ein Viertel der Bevölkerung in Deutschland nimmt regelmäßig Nahrungsergänzungsmittel ein, von denen wiederum 11% Vitamin E enthalten [1]. Diese Supplemente können bis zu 1000 I.E. pro Dosis enthalten, was ca. 60-mal höher ist als die empfohlenen 16–22 I.E. pro Tag [2]. Da gerade ältere Menschen häufig Medikamente einnehmen müssen, sind mögliche Wechselwirkungen von Vitamin E mit Arzneistoffen von zunehmender Bedeutung.



Publikationsverlauf

Artikel online veröffentlicht:
07. Juni 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Max Rubner-Institut . Nationale Verzehrsstudie II: Ergebnisbericht Teil 2, 2008. Im Internet http://www.mri.bund.de/fileadmin/Institute/EV/NVSII_Abschlussbericht_Teil_2.pdf
    PubMed
  • 2 Wolfram G. New reference values for nutrient intake in Germany, Austria and Switzerland (DACH-Reference Values). Forum Nutr 2003; 56: 95-97
    PubMedSuche in Google Scholar
  • 3 Lown KS, Bailey DG, Fontana RJ. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553
    CrossrefPubMedSuche in Google Scholar
  • 4 Dürr D, Stieger B, Kullak-Ublick GA. et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604
    CrossrefPubMedSuche in Google Scholar
  • 5 Fasco MJ, Principe LM. R- and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem 1982; 257: 4894-4901
    CrossrefPubMedSuche in Google Scholar
  • 6 Podszun M, Frank J. Vitamin E-drug interactions: molecular basis and clinical relevance. Nutr Res Rev 2014; 27: 215-231
    CrossrefPubMedSuche in Google Scholar
  • 7 Podszun MC, Frank J. Vitamin E-drug interactions. In: Weber P, Birringer M, Blumberg JB et al., Hrsg. Vitamin E in Human Health. Cham: Humana Press 2019; 247-260
    CrossrefPubMedSuche in Google Scholar
  • 8 Williams RT. Detoxication Mechanisms: The Metabolism of Drugs and Allied Organic Compounds. London: Champan & Hall; 1947
    Suche in Google Scholar
  • 9 Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
    CrossrefPubMedSuche in Google Scholar
  • 10 Uhlén M, Fagerberg L, Hallström BM. et al. Tissue-based map of the human proteome. Science 2015; 347: 6220
    CrossrefPubMedSuche in Google Scholar
  • 11 Zhou C, Tabb MM, Sadatrafiei A. et al. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004; 32: 1075-1082
    CrossrefPubMedSuche in Google Scholar
  • 12 Abuznait A, Patrick SG, Kaddoumi A. Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity. J Pharm 2011; 14: 236-248
    CrossrefPubMedSuche in Google Scholar
  • 13 Podszun MC, Jakobi M, Birringer M. et al. The long chain α–tocopherol metabolite α-13’-COOH and γ- tocotrienol induce P-glycoprotein expression and activity by activation of the pregnane X receptor in the intestinal cell line LS 180. Mol Nutr Food Res 2016; 61: 1-9
    CrossrefPubMedSuche in Google Scholar
  • 14 Mustacich DJ, Gohil K, Bruno RS. et al. Alpha-tocopherol modulates genes involved in hepatic xenobiotic pathways in mice. J Nutr Biochem 2009; 20: 469-476
    CrossrefPubMedSuche in Google Scholar
  • 15 Chan L, Humma LM, Schriever CA. et al. Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-GP) in humans. Clin Pharmacol Ther 2004; 75: P95
    CrossrefPubMedSuche in Google Scholar
  • 16 Duhem N, Danhier F, Préat V. Vitamin E-based nanomedicines for anti-cancer drug delivery. J Control Release 2014; 182: 33-44
    CrossrefPubMedSuche in Google Scholar
  • 17 Hundhausen C, Frank J, Rimbach G. et al. Effect of vitamin E on cytochrome P450 mRNA levels in cultured hepatocytes (HepG2 ) and in rat liver. Animals 2006; 190: 183-190
    PubMedSuche in Google Scholar
  • 18 Kluth D, Landes N, Pfluger P. et al. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med 2005; 38: 507-514
    CrossrefPubMedSuche in Google Scholar
  • 19 Podszun MC, Grebenstein N, Spruss A. et al. Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of guinea pigs. J Nutr Biochem 2014; 25: 573-579
    CrossrefPubMedSuche in Google Scholar
  • 20 Leonard SW, Joss JD, Mustacich DJ. et al. Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins. Am J Health Syst Pharm 2007; 64: 2257-2266
    CrossrefPubMedSuche in Google Scholar
  • 21 Clarke MW, Burnett JR, Wu JHY. et al. Vitamin E supplementation and hepatic drug metabolism in humans. J Cardiovasc Pharmacol 2009; 54: 491-496
    CrossrefPubMedSuche in Google Scholar
  • 22 Blackhall ML, Fassett RG, Sharman JE. et al. Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 1970-1975
    CrossrefPubMedSuche in Google Scholar
  • 23 de Vries APJ, Oterdoom LH, Gans ROB, Bakker SJL. Supplementation with anti-oxidants Vitamin C and E decreases cyclosporine A trough-levels in renal transplant recipients. Nephrol Dial Transplant 2006; 21: 231-232
    CrossrefPubMedSuche in Google Scholar
  • 24 Pichard L, Domergue J, Fourtanier G. et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 1996; 51: 591-598
    CrossrefPubMedSuche in Google Scholar
  • 25 Bárány P, Stenvinkel P, Ottosson A. et al. Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers. Nephrol Dial Transpl 2001; 16: 580-584
    CrossrefPubMedSuche in Google Scholar
  • 26 Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258
    CrossrefPubMedSuche in Google Scholar
  • 27 Ali M, Gudbranson C, McDonald J. Inhibition of human platelet cyclooxygenase by alpha-tocopherol. Prostaglandins Med 1980; 4: 79-85
    CrossrefPubMedSuche in Google Scholar
  • 28 Freedman JE, Keaney JF. Vitamin E inhibition of platelet aggregation is independent of antioxidant activity. J Nutr 2001; 131: 374S-377S
    CrossrefPubMedSuche in Google Scholar
  • 29 Freedman JE, Farhat JH, Loscalzo J, Keaney JF. alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996; 94: 2434-2440
    CrossrefPubMedSuche in Google Scholar
  • 30 Liede K, Haukka J, Saxén LM, Heinonen OP. Increased tendency towards gingival bleeding caused by joint effect of α-tocopherol supplementation and acetylsalicylic acid. Ann Med 1998; 30: 542-546
    CrossrefPubMedSuche in Google Scholar
  • 31 Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62: 1381S-1384S
    CrossrefPubMedSuche in Google Scholar
  • 32 Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem 2002; 277: 25290-25296
    CrossrefPubMedSuche in Google Scholar
  • 33 Bardowell SA, Ding X, Parker RS. Disruption of P450-mediated vitamin E hydroxylase activities alters vitamin E status in tocopherol supplemented mice and reveals extra-hepatic vitamin E metabolism. J Lipid Res 2012; 53: 2667-2676
    CrossrefPubMedSuche in Google Scholar
  • 34 Edson KZ, Prasat B, Unadkat JD. et al. Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 2013; 52: 8276-8285
    CrossrefPubMedSuche in Google Scholar
  • 35 Hirsh J, Dalen J, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S
    CrossrefPubMedSuche in Google Scholar
  • 36 Corrigan JJ, Ulfers LL. Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency. Am J Clin Nutr 1981; 34: 1701-1705
    CrossrefPubMedSuche in Google Scholar
  • 37 Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996; 77: 545-546
    CrossrefPubMedSuche in Google Scholar
  • 38 Cheung MC, Zhao X-Q, Chait A. et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001; 21: 1320-1326
    CrossrefPubMedSuche in Google Scholar
  • 39 Brown BG, Zhao X-Q, Chait A, Fisher L. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseases. N Engl J Med 2001; 345: 1583-1592
    CrossrefPubMedSuche in Google Scholar
  • 40 Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 2004; 11: 174-182
    CrossrefPubMedSuche in Google Scholar